The themes MaxCyte is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
基于 MaxCyte, Inc. 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
US$1.20+1.7%11月13日 收盘
数据截至2026年9月30日,来自2026年11月10日提交的10-Q
公司指引:2026 财年营收 约 US$34.5M — 同比增长 4.5%,低于刚公布的 48.7%
Just reported
From MaxCyte's results release of 2026年11月10日; its quarterly report has since been filed.
Actual
US$10.2M
+49% y/y
+40% q/q
Guided
—
No guide given
Actual
-US$0.05
Guided
—
No guide given
Actual
-US$6M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade C-
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 MaxCyte, Inc. 评级历史 20 个季度中的 2 个。 其余 18 个可回溯到 2022年3月。